SNDX Q1 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$27M-7167.0% margin

Net Income

-$28M-7314.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$280M

Total Liabilities

$51M

Stockholders' Equity

$228M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$27M	-$15M	-79.9%
Net Income	-$28M	-$15M	-82.0%